Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers at UT Southwestern Identify Novel Class of Drugs for Prostate Cancers

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
Researchers found that they could disrupt androgen receptor signaling using peptidomimetics.

A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.

In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling, which is driven by androgens, such as testosterone.

To thwart tumor growth, most patients with advanced prostate cancer receive drugs that block the production of androgen or block the receptor where the androgen binds.

Unfortunately, such treatments invariably fail and patients die of prostate cancer with their androgen receptor signaling still active and still promoting tumor growth.

In the new study, available online at Nature Communications, a team of researchers led by Dr. Ganesh Raj, associate professor of urology at UT Southwestern, found that they could disrupt androgen receptor signaling using a novel class of drugs called peptidomimetics.

This therapeutic agent consists of an engineered small protein-like chain designed to mimic peptides that are critical for androgen receptor function.

The peptidomimetic agents block the activity of the androgen receptor even in the presence of androgen by attacking the protein in a different spot from where the androgen binds.

“We are hopeful that this novel class of drugs will shut down androgen receptor signaling and lead to added options and increased longevity for men with advanced prostate cancer,” said Dr. Raj, the senior author of the study.

Dr. Raj compared the action that takes place to a lock and key mechanism. In prostate cancer, the androgen receptor (lock) is activated by the androgen (key) resulting in a signal that causes prostate cancer proliferation.

In advanced prostate cancer, despite drugs targeting either the lock (androgen receptor) or the key (androgen production), there can be aberrant keys that open the lock or mutated locks that are always open, resulting in cancer cell proliferation.

Instead of trying to block the lock or the key, peptidomimetics uncouple the lock and key mechanism from the proliferation signal. Thus, even with the androgen receptor activated, the prostate cancer cells do not receive the signal to proliferate and do not grow.

The researchers tested their drug in mouse and human tissue models. The novel drug proved non-toxic and prevented androgen receptor signaling in cancer cells.

The response is highly promising and suggests that peptidomimetic targeting of prostate cancer may be a viable therapeutic approach for men with advanced disease.

Further testing is needed before a drug could move to Phase 1 clinical trials that involve human participants.

“Most drugs now available to treat advanced prostate cancer improve survival rates by three or four months,” Dr. Raj said. “Our new agents may offer hope for men who fail with the current drugs.”

These findings represent the development of a first-in-class agent targeting critical interactions between proteins. Other cellular and disease processes eventually could also be targeted with peptidomimetics, the scientists said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UT Southwestern Scientists Synthesize Nanoparticles
Synthetic nanoparticles to deliver tumor-suppressing therapies to damaged livers.
Wednesday, January 27, 2016
Tumor-suppressing Gene Works by Restraining Mobile Genetic Elements
Findings from the study leads to new ways of diagnosing and treating cancer.
Saturday, January 23, 2016
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Friday, January 22, 2016
Researchers Find a Small Protein that Plays a Big Role in Heart Muscle Contraction
New protein, DWORF, stimulates a calcium-ion pump that controls muscle contraction.
Friday, January 15, 2016
UT Southwestern Scientists Discover a New Role for RNA
Safeguarding chromosome number in human cells, with implications for cancer biology.
Wednesday, December 30, 2015
UT Southwestern Scientist Honored as Rising Star in Texas Research
Dr. Joshua Mendell selected as the recipient of the 2016 Edith and Peter O’Donnell Award in Medicine.
Saturday, December 12, 2015
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Saturday, October 10, 2015
UT Southwestern Biochemist Receives NIH Early Independence Award
Dr. William Israelsen studies on hibernation may aid the fight against cancer.
Wednesday, October 07, 2015
Researchers Discover Molecule that Accelerates Tissue Regeneration
Newly discovered molecule, SW033291 accelerate cell recovery following bone marrow transplants.
Friday, June 12, 2015
UT Southwestern Faculty Members Named HHMI Investigators
Appointment of Dr. Kim Orth and Dr. Joshua Mendell to HHMI.
Saturday, May 23, 2015
Scientists Identify Key Receptors Behind Development of AML
Blocking ITIM-receptor signaling in combination with conventional therapies may represent a novel strategy for AML treatment.
Saturday, May 02, 2015
Study Reveals Molecular Genetic Mechanisms Driving Breast Cancer Progression
The findings are published online and in the journal Molecular Cell.
Saturday, April 04, 2015
New Cyclotron Facility at UT Southwestern
Expands research opportunities and imaging capabilities for detecting, tracking cancer.
Friday, March 20, 2015
Acetate Supplements Shown to Speed Up Cancer Growth
A major compound produced in the gut by host bacteria.
Friday, February 20, 2015
MAGE Genes Provide Insight into Optimizing Chemotherapy
UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.
Tuesday, February 17, 2015
Scientific News
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!